Danske Bank A S Purchases New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Danske Bank A S bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 132,217 shares of the medical equipment provider’s stock, valued at approximately $11,383,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Dodge & Cox increased its position in Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock valued at $2,113,736,000 after acquiring an additional 290,676 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Zimmer Biomet by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after purchasing an additional 192,517 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $1,344,282,000. State Street Corp increased its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after purchasing an additional 195,214 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insiders Place Their Bets

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $101.01 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The stock has a market cap of $19.27 billion, a P/E ratio of 24.58, a price-to-earnings-growth ratio of 2.69 and a beta of 0.45. The stock’s 50-day moving average price is $92.64 and its two-hundred day moving average price is $91.00.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the prior year, the business posted $2.07 EPS. Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on ZBH shares. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Wells Fargo & Company decreased their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 29th. Barclays lowered their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Finally, Citigroup lowered their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.